Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. - Wikidata - wikimedia - TriplyDB

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

http://www.wikidata.org/entity/Q35030557

about

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games Infliximab-Related Infusion Reactions: Systematic Review Leukocyte adhesion molecules in animal models of inflammatory bowel disease Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet.Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy.Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.Extraintestinal manifestations in inflammatory bowel disease.Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF How reliable are sino-nasal cell lines for studying the pathophysiology of chronic rhinosinusitis?Profile of soluble cytokine receptors in Crohn's disease.Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy Current therapy of ulcerative colitis in children.Biologics in inflammatory bowel disease: how much progress have we made?Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature.Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy.TNFalpha blockade in human diseases: an overview of efficacy and safety.Safety of biologic therapy.Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).Treatment of inflammatory bowel disease: a review of medical therapy.Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.Use of infliximab in particular clinical settings: management based on current evidence.Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.Emerging biologics in the treatment of uveitis.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Acute infusion reactions induced by monoclonal antibody therapy.Use of biological molecules in the treatment of inflammatory bowel disease.Longitudinal Patterns of Medication Nonadherence and Associated Health Care Costs.Review of local injection of anti-TNF for perianal fistulising Crohn's disease.Transmembrane TNF-α Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF-β: Therapeutic Implications.Anaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed.How the immune system responds to therapeutic biological agents.Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy.Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial.Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial.Perforating Crohn's ileitis: delay of surgery is associated with inferior postoperative outcome.Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis.The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.

P2860

Q24683018-5851BB70-B4C6-4A4F-9686-67E83CAF7BA9 Q27013835-899D0DB4-B3E6-4310-B1A0-70CAC241D5B8 Q30437758-EAB09244-361B-4990-B236-F6869B05717C Q33501390-D7E1767C-64CA-4244-A38D-1656BDF7DBF6 Q33879437-9B13471A-3C41-473F-A51F-94FC3D2F548C Q34336510-5BA36AF4-13B8-4259-A9DD-46CC4C0E0941 Q34476049-EEF98298-3B46-4921-A072-FC7A857847C4 Q34488386-3C3C1B84-0D93-4533-B398-A16F050D1C8B Q35553478-0F60CD54-D335-4006-98A6-CABD36AD0BEC Q35578178-7CFEB9BA-D954-4418-8CDB-C4508C87728E Q35597272-DCD0106D-A9A3-459D-8FBA-FBD0E526DF30 Q35597763-294904A6-F47F-466F-BB2D-BC1236D3BC1C Q35609674-F8BA7822-787D-4735-9B25-CD0788DD86F1 Q35861158-8A095DA9-03B4-4A85-BDFA-7474F0064EEC Q36150895-8E6B96EC-8C7D-4670-BA92-7025912E1ECA Q36326517-7AA71886-13F1-4549-8A6F-536B4FA28846 Q36536861-14A2C1C6-F9E1-437F-B1D6-F661218DB3A7 Q36737339-E93FFC27-4781-49F9-B7C2-CF0EE87A1B12 Q36920423-15CCDADC-9AE0-4FD5-9AE1-F508F1ED1BE5 Q37058862-83887A43-3146-449C-B2F8-F67755D17DCB Q37188711-A83F4B92-9B32-4A9C-B726-03F787AF6304 Q37506064-26FC25A5-3457-472B-8459-39E2F0AAB673 Q37625267-79CABC29-787E-490C-A873-3F3459C0C72B Q37754665-DD730793-8E7E-41C1-931B-65E6507E2628 Q37814549-CB1EA826-9A33-42CA-92F3-ED761FB5A790 Q37821495-641F447B-65CA-42DC-ACCC-EC4190B4C46D Q37829470-3143F5EF-AF23-4FD6-A183-CB017907A50A Q38724407-E64AED3B-7331-446D-B8C0-4B6313A72A98 Q40044303-287EB872-1F76-44F0-8435-18B742D5B18D Q40146734-E4C201E9-AB98-47C9-B1E3-CE67BDEC2994 Q40280954-DAA84EFB-1641-4D6F-8385-A91BF2BDF976 Q41882370-7D3DE36B-AE5B-4072-80DD-1642415DE0CF Q42032750-F29B56F1-F789-47FF-B85E-6706CB1F0591 Q42375893-3C1A2431-030F-436D-B9B7-742642512661 Q42410013-AFB7B671-BBDE-4ABC-B8B9-B5F784B467B6 Q42708758-5A0A41A2-60DD-4C3C-A46A-B583CB697719 Q42905037-6F1C1B02-5698-46D6-9430-FA0876491ECE Q44884726-C84675D4-6975-475D-A259-79A51B634A5C Q45004851-D2227D71-4E5D-488D-8805-51945637CB6D Q45031722-547C9163-BF7F-4815-885C-E5C7A17EB4F4

P2860

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

http://www.wikidata.org/entity/Q35030557

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@ast

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@en

type

label

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@ast

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@en

prefLabel

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@ast

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@en

P1433

Q35030557-D603D949-6BF4-4C9B-9D21-0C5B0DB6E41B

P1476

Q35030557-648484F1-6FF0-4748-9CE3-9F4CED79012D

P2093

Q35030557-5348B727-E86E-4442-902F-E84335325E9D

P2860

Q35030557-04F2D92E-D5EE-43F4-97F3-F22A70123803

Q35030557-1363BF5E-029D-40CF-80F2-D9BB01A2BC14

Q35030557-15F441BE-1B54-4A01-98F7-C95F5DD7B0E8

Q35030557-1FB8016A-DE5A-4065-8417-EDFF44AE628A

Q35030557-203CB662-7762-4D09-9F71-673EEB8914BD

Q35030557-217CBCFA-6E9E-476E-8B86-22A8D10094FA

Q35030557-29BC358D-BED7-443B-BD29-5C02AF074CCA

Q35030557-300B1AB2-9C72-4ABC-BE2B-893D9591D3A9

Q35030557-38BDE96C-9ED4-4888-A5EB-1684B2F84D6E

Q35030557-788AF3C9-410C-48F1-A4CB-8189E41C7C9F

P304

Q35030557-24DB5AC3-0BDF-4646-9675-F98845042C22

P31

Q35030557-5CEE81C7-31EE-4E98-9E6D-D03EB72D071B

P356

Q35030557-5B7DFF36-AA84-451D-9068-63F2E7B47445

P407

Q35030557-2D677326-19DD-4F20-B98D-7D5126FA2B08

P433

Q35030557-8BCF1FFB-6802-42FB-81F6-DFF386A69EFF

P478

Q35030557-B9611259-868E-4719-AC94-4D7CADE16C57

P50

Q35030557-76CA85A5-4562-4FC9-8C3E-AD38C6210344

P577

Q35030557-B801BC2B-3AD6-44EB-AAB5-DA0E2312F7C0

P5875

Q35030557-4B4C2211-0956-4FCA-A040-C5AB3E85F4A9

P698

Q35030557-0C4FA922-DCB7-43F7-9570-3BD7F3AAA24E

P921

Q35030557-D63B1C08-0DC7-484E-8F2D-D4F1F8699DD8

P356

J.1572-0241.2002.07093.X

P1433

The American Journal of Gastroenterology

P1476

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

@en

P2093

Stephen B Hanauer

http://www.w3.org/2001/XMLSchema#string

P2860

Management of Crohn's disease in adults

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Infliximab for the treatment of orofacial Crohn's disease.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.

P304

2962-2972

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2002.07093.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10982550

http://www.w3.org/2001/XMLSchema#string

P698

12492177

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease